Skip to main content

Advertisement

SpringerLink
Log in

Stroke prevention in atrial fibrillation

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Nonvalvular atrial fibrillation (AF) is an independent risk factor for stroke. The overall risk of ischemic stroke in patients experiencing AF without prior stroke averages about 5% per year, but varies depending on the presence of coexistent thromboembolic risk factors. Patients with AF with low (about 1% per year), moderate (2%–4% per year) and high (≥ 6% per year) stroke risks have been identified, but the generalizability of available risk stratification schemes to clinical practice has not been defined. Adjusted-dose warfarin (target International Normalized Ratio [INR] 2–3) is highly efficacious for prevention of stroke in patients with AF (about 60% reduction) and is relatively safe for selected patients, if carefully monitored. Aspirin has a modest effect on reducing stroke (about 20% reduction). The role of transesophageal echocardiography is routine management of AF remains unsettled. Warfarin therapy should be considered for patients with AF predicted to have a high risk of stroke and who can safely receive it. Aspirin may be indicated for patients with AF at low risk for stroke and for those who cannot safely receive adjusted-dose warfarin. For those with moderate stroke risk, individual bleeding risks during anticoagulation and patient preferences should guide antithrombotic therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation: A major contributor to stroke in the elderly. Arch Intern Med 1987, 147 1561–1564.

    Article  PubMed  CAS  Google Scholar 

  2. Wolf PA, Abbot RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991, 22:983–988.

    PubMed  CAS  Google Scholar 

  3. Hart RG, Pearce LA, Miller VT, et al.: Cardioembolic vs. noncardioembolic stroke in atrial fibrillation: Frequency and effect of antithrombotic agents. Cerebrovascular Dis 1999, in press.

  4. Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized clinical trials. Arch Intern Med 1994, 154:1949–1957.

    Google Scholar 

  5. Atrial Fibrillation Investigators: The efficacy of aspirin in patients with atrial fibrillation: Analysis of pooled data from three randomized trials. Arch Int Med 1997, 157:1237–1240.

    Article  Google Scholar 

  6. Hart RG, Benavente O, McBride R, Pearce LA: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med 1999, 131:492–501. Most complete summary to date of randomized clinical trials testing antithrombotic therapies in atrial fibrillation. Details about inconsistent effects of aspirin are discussed.

    PubMed  CAS  Google Scholar 

  7. Kopeck SL, Gersh BJ, McGoon MD, et al.: The natural history of lone atrial fibrillation: A population-based study over three decades N Engl J Med 1987, 317:669–674.

    Article  Google Scholar 

  8. Atrial Fibrillation Investigators: Echocardiographic predictors of stroke in patients with atrial fibrillation: A prospective study of 1,066 patients from three clinical trials. Arch Int Med 1998, 158:1316–1320.

    Article  Google Scholar 

  9. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation I: Clinical features in patients at risk. Ann Int Med 1992, 116:1–5.

    Google Scholar 

  10. Stroke Prevention in Atrial Fibrillation Investigators: Predictors of thromboembolism in atrial fibrillation II: Echocardiographic features in patients at risk. Ann Int Med 1991, 1:6–12.

    Google Scholar 

  11. Stroke Prevention in Atrial Fibrillation Investigators: Risk factors for thromboembolism during aspirin therapy in atrial fibrillation. J Stroke Cerebrovasc Dis 1995, 5:147–157.

    Article  Google Scholar 

  12. Hart RG, Pearce LA, McBride R, et al.: Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: Analysis of 2012 participants in the SPAF I-III Clinical Trials. Stroke 1999, 30:1223–1229. Recent in-depth analysis of predictors of stroke. Postmenopausal hormone use was associated with increased risk, while regular alcohol use was associated with reduced stroke risk.

    PubMed  CAS  Google Scholar 

  13. Blackshear JL, Pearce LA, Asinger RW, et al.: Mitral regurgitation associated with reduced thromboembolic events in high risk patients with atrial fibrillation J Am Coll Cardiol 1993, 73:840–843.

    Google Scholar 

  14. Stollberger C, Chnupa P, Kronik G, et al.: Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. Ann Int Med 1998, 128:630–638.

    PubMed  CAS  Google Scholar 

  15. Stroke Prevention in Atrial Fibrillation Committee on Echocardiography: Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with atrial fibrillation. Ann Int Med 1998, 128:639–647. Thought-provoking results of a large prospective study of transesophageal echocardiography in atrial fibrillation. Importance of aortic arch plaque is a surprise finding.

    Google Scholar 

  16. Laupacis A, Albers GW, Dalen JE, et al.: Antithrombotic therapy in atrial fibrillation. Chest 1998, 114 (suppl):579S-589S. Latest recommendations of a consensus conference on antithromboticmanagement in atrial fibrillation.

    PubMed  CAS  Google Scholar 

  17. Stroke Prevention in Atrial Fibrillation Investigators: Prospective identification of patients with nonvalvular atrial fibrillation at low-risk of stroke during treatment with aspirin. JAMA 1998, 279:1273–1277. Validation of a risk stratification scheme demonstrating that patients with atrial fibrillation with low stroke risks can be identified.

    Article  Google Scholar 

  18. Feinberg WM, Kronmal RA, Newman AB, et al.: Stroke risk in an elderly population with nonvalvular atrial fibrillation: The Cardiovascular Health Study. J Gen Int Med 1999, 14:56–59.

    Article  CAS  Google Scholar 

  19. Stroke Prevention in Atrial Fibrillation Investigators: Adjusteddose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: The Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet 1996, 348:633–638.

    Article  Google Scholar 

  20. Hylek EM, Skates SJ, Sheehan MA, Singer DE: An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996, 335:540–546.

    Article  PubMed  CAS  Google Scholar 

  21. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators: The effect of low-dose warfarin on the risk of stroke in nonrheumatic atrial fibrillation. N Engl J Med 1990, 323:1505–1511.

    Article  Google Scholar 

  22. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators: Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992, 327:1406–1412.

    Article  Google Scholar 

  23. Stroke Prevention in Atrial Fibrillation Investigators: Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994, 343 687–691.

    Google Scholar 

  24. Man-Son-Hing M, Laupacis A, O'Connor A, Wells G: Warfarin for atrial fibrillation: The patient perspective. Arch Int Med 1996, 156:1841–1848.

    Article  CAS  Google Scholar 

  25. Stroke Prevention in Atrial Fibrillation Investigators: Bleeding during antithrombotic therapy for atrial fibrillation. Arch Int Med 1996:156:411–416.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine (Neurology), University of Texas Health Science Center, 7703 Floyd Curl Drive, 78284-7883, San Antonio, TX, USA

    Robert G. Hart MD

Authors
  1. Robert G. Hart MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hart, R.G. Stroke prevention in atrial fibrillation. Curr Cardiol Rep 2, 51–55 (2000). https://doi.org/10.1007/s11886-000-0025-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-000-0025-2

Keywords

Search

Navigation